

Tonga

Population 2015

<1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	<0.01 (<0.01–<0.01)	1.2 (0.77–1.8)
Mortality (HIV+TB only)	0 (0–0)	0 (0–0)
Incidence (includes HIV+TB)	0.016 (0.014–0.019)	15 (13–17)
Incidence (HIV+TB only)	0 (0–0)	0.02 (0.01–0.02)
Incidence (MDR/RR-TB)**	<0.01 (0–<0.01)	0.79 (0.44–1.1)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	<0.01 (<0.01–<0.01)	<0.01 (<0.01–<0.01)	<0.01 (<0.01–<0.01)
Males	<0.01 (<0.01–<0.01)	<0.01 (<0.01–0.01)	<0.01 (<0.01–0.011)
Total	<0.01 (<0.01–<0.01)	0.014 (0.012–0.015)	0.016 (0.014–0.019)

TB case notifications, 2015	
Total cases notified	14
Total new and relapse	14
- % tested with rapid diagnostics at time of diagnosis	100%
- % with known HIV status	100%
- % pulmonary	43%
- % bacteriologically confirmed among pulmonary	100%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.08 (0.05–0.12)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	0	0%
- on antiretroviral therapy	0	

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			0 (0–0)
Estimated % of TB cases with MDR/RR-TB	5.2% (3.1–7.3)	28% (25–30)	
% notified tested for rifampicin resistance	0%		0
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 0, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	100%	13
Previously treated cases, excluding relapse, registered in 2014		0
HIV-positive TB cases, all types, registered in 2014		0
MDR/RR-TB cases started on second-line treatment in 2013		0
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	<1

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB